Latest news with #LIB
Cosmopolitan
a day ago
- Entertainment
- Cosmopolitan
‘Love Is Blind' Season 9 - News, Cast, Updates, More
Listen, I know it feels like Love Is Blind season 8 just concluded (congrats to Daniel Hastings and Taylor Haag!), but a new season is already on its way. This time, the pods are are in Denver, Colorado, where a new batch of singles will take a chance at finding love sight unseen. Will we get another LIB success story out of this season? Your guess is as good as mine! Here's what we know so far. Yep!! And believe it or not, casting for this season actually began waaay back in August 2023 (peep that last slide below). Since then, Netflix has renewed the unscripted dating series through season 10, so you can look forward to at least two more seasons spent in the pods. The ninth installment of LIB drops on October 1, so get ready, friends. Last season consisted of 13 hour-long episodes (as well as a reunion episode), so you can probably expect the same for this coming season. Likewise, if season 9 follows the same pattern as season 8, here's when you can expect new episodes to drop: Not yet, but you better believe we'll be updating this once it drops. Also tbd! Stand by.
Cosmopolitan
4 days ago
- Entertainment
- Cosmopolitan
‘Love Is Blind' Stars Sara and Joey Are Officially Dating
Sara Carton and Joey Leveille may not have been a couple on season 8 of Love Is Blind, but the cast members came out of the pods with a connection of their own. On Sunday, July 13, Sara and Joey debuted their 'ship with a joint Instagram post, which showed them on a rooftop, kissing for the camera. 'Happy 🥹. My newest life chapter title,' the caption read. Their relationship came as a shock to fans of the Netflix reality series, who watched them explore relationships with other people during the season. '😮 so it's trueee LIB works just not on camera lol,' one fan wrote, while another added, 'Wait a darn minute!!! I'm gonna have to go rewatch this season. 😂😂.' In case you need a refresher: Joey was originally coupled with Monica Danús and made it to the altar on the eighth season of Love Is Blind, but they decided not to go through with the marriage. Sara also made it out of the pods with her original partner, Ben Mezzenga, but later called off the wedding. Though Ben asked if she would want to explore their connection off the show, she stood on business when it came to her decision. 'If you're going to say no to that [marriage], why even continue the relationship?' she told People during an exit interview. 'That's been a theme of mine where I know in the past, my past relationships, I know that this person isn't my person, but oh, maybe they can change, or maybe there was potential there. I can see us growing together. And I didn't want to continue the cycle of that.' Sara and Joey's hard-launch comes after Sara denied she was dating Joey during an episode of The Viall Files in March. 'To be clear, me and Joey are not dating,' she said, later adding, 'I don't know what the future will hold. I definitely have no capacity to even think about a relationship.' Then, during a May appearance on the Dear Shandy podcast, she clarified that they weren't 'dating officially' but that they were exploring their relationship. 'To keep it short and concise right now, a lot of people think of dating in different terms, so to keep it clear, dating officially—like boyfriend-girlfriend—we're not,' Sara explained at the time. 'We are dating in the sense of exploring our relationship and getting to know one another.' As for their exes, Monica and Ben, who sparked dating rumors of their own? Sorry to report that those two actually are just friends. On the Girl Please podcast back in April, Ben said of himself and Monica, 'We're not intentionally trolling, just having fun making content together and just letting the world take it as they want.'
Business Wire
06-05-2025
- Business
- Business Wire
LIB Therapeutics Announces Key Results from Presentations at 2025 European Atherosclerosis Society Meeting in Glasgow May 5-6
CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company advancing Lerodalcibep (LeroChol ®), a novel, monthly, small dose third-generation PCSK9 inhibitor today announced results presented at the May 5-7 2025 European Atherosclerosis Society meeting in Glasgow. LERODALCIBEP ADJUDICATED CARDIOVASCULAR EVENTS IN A PRE-DEFINED POOLED ANALYSIS OF THREE LARGE LONG TERM PHASE III STUDIES – Dr David Kallend May 5th As part of the safety analysis, a prespecified exploratory endpoint of major adverse cardiovasular events (MACE) adjudicated by a blinded Clinical Events Committee of all serious CV adverse events. A patient-level, pre-defined pooled analysis of the pivotal placebo-controlled Phase III studies (LIBerate-HR, LIBerate-CVD and LIBerate-HeFH), included patients on maximally tolerated statin with or without other oral lipid-lowering-therapy. Patients were randomized 2:1 to 300mg lerodalcibep or placebo monthly SC for 24 (LIBerate-HeFH) or 52 weeks (LIBerate-HR and LIBerate-CVD). *placebo adjusted mITT analysis; # MACE = composite of death, resuscitated cardiac arrest, acute myocardial infarction (STEMI and NSTEMI), hospitalization for unstable angina, stroke and coronary revascularization The early and large risk reductions in MACE of 45% to 50% provide encouraging insights into the potential CV benefits of lowering LDL-C with lerodalcibep and these findings await confirmation in a planned large definitive CV outcomes trial to start Q3 this year. PHASE 3 POOLED LONG-TERM SAFETY AND EFFICACY OF LERODALCIBEP IN PATIENTS WITH ASCVD, HEFH, VERY HIGH OR HIGH RISK FOR ASCVD – David Kallend May 6 Pooled safety and efficacy was assessed from the key three blinded placebo-controlled Phase 3 trials (LIBerate-CVD, LIBerate-HR and LIBerate-HeFH) in patients with atherosclerotic cardiovascular disease (ASCVD), very high or high risk for ASCVD on stable maximally tolerated statin therapy and additional oral agents. The mean (SE) placebo-adjusted reductions in LDL-C at (Weeks 24 and 52 respectively) 'trough' with lerodalcibep were; mITT analysis was, 58.6(1.3)% and 59.0(1.5)%, ITT with imputation was 54.9(1.4)% and 52.3(1.7)% Per-Protocol analysis was 61.8(1.4)% and 62.3(1.5)% The placebo adjusted LDL-C reduction at 'peak' (2 week post dose) in the mITT population was 73.7% at Week 50 and the mean of weeks 50 and 52 was 66.0(1.3)%. On lerodalcibep, 83% of subjects at Week 24 and 90% of subjects at Week 52 achieved both ESC/EAS recommended targets of >50 additional LDL-C reduction and their new lower targets. Lerodalcibep was well tolerated with 90.3% and 88.7% of subjects completing the study at Weeks 24 and 52 respectively Adverse events were similar between groups, other than more mild injection site reactions (ISRs) on lerodalcibep. The few and sporadic in-vitro anti-drug antibodies had no impact on efficacy or safety. 'We are very pleased and encouraged by the results from the pooled key registration trials, which were large, of long duration, and placebo-controlled,' said Dr. David Kallend, Chief Medical Officer of LIB Therapeutics. 'The data demonstrates substantial and durable reductions in LDL-C - both in absolute terms and percentage change - as well as in other atherogenic lipoproteins such as Lp(a) and ApoB.' He continued, 'Lerodalcibep was well tolerated with no safety concerns or drug-drug interactions, especially important for patients with CVD already on multiple other oral therapeutic agents. Its patient-friendly profile, including the only monthly, 12 doses per year, single small-volume SC injection which along with long-term ambient stability not requiring refrigeration by patients, makes it especially well-suited for patients with CVD or at high-risk for CVD, including those with FH, to help them achieve the new, more aggressive LDL-C targets and maintain life long adherence to therapy.' 'While the number of CV events in the pooled phase trials was limited, the early, large, and statistically significant reductions in MACE are highly encouraging. We look forward to initiating a differentiated cardiovascular outcomes trial to further explore and confirm these findings.' About Lerodalcibep Lerodalcibep is a novel, small protein-binding, third-generation PCSK9 inhibitor, and has been developed as a more convenient, once-monthly, single small-volume, subcutaneous injection that will not require refrigeration at home or in travel. These features make Lerodalcibep a unique alternative to approved PCSK9 inhibitors. The anti-PCSK9 binding domain of Lerodalcibep is an 11-kDa polypeptide called an adnectin, engineered for high-affinity subnanomolar binding to human PCSK9 and fused to human serum albumin to enhance plasma half-life. In clinical trials, Lerodalcibep has demonstrated sustained LDL-C reductions of ≥60% in patients with, or at very-high or high risk of, cardiovascular disease (CVD) and ≥50% in those with heterozygous familial hypercholesterolemia (FH) who have more severe LDL-C elevations, and is expected to expand treatment options for the millions of patients around the world with CVD, including the 30 million individuals with FH. The global Phase 3 LIBerate program enrolled a diverse population of over 2,900 patients with CVD, without CVD at very high and high risk for CVD, including heterozygous and homozygous familial hypercholesterolemia. Lerodalcibep was dosed once monthly for up to 52 weeks in these key registration-enabling, placebo-controlled trials, and over 2,400 patients have continued in the 72-week open-label extension trial. Following the FDA BLA submission, LIB is preparing a Marketing Authorization Application to the European Medicines Agency. LIB submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in December 2024, and received formal filing by FDA in February with and anticipated PDUFA date in mid Dec this year. LIB is seeking approval of lerodalcibep to reduce LDL-C for the treatment of patients with atherosclerotic cardiovascular disease (ASCVD), or very high or high risk of ASCVD, and primary hyperlipidemia, including heterozygous and homozygous familial hypercholesterolemia (HeFH / HoFH). About LIB Therapeutics Inc. LIB Therapeutics is a privately-held, late-stage biopharmaceutical company dedicated to bringing Lerodalcibep to the millions of patients with cardiovascular disease and to the 30 million individuals with familial hypercholesterolemia (FH) around the world, who require additional large reductions in LDL-C, despite maximally tolerated statins and other lipid lowering agents, to achieve LDL-C goals.
CTV News
29-04-2025
- Politics
- CTV News
Election results for London, Ont. ridings
A sign outside an Elections Canada voting station on March 25, 2025. It's federal election season, and around the London, Ont. region, there are five ridings to follow. It's the first election since the ridings were redistributed. 032425_london election ridings districts population area middlesex centre The riding of Middlesex-London (Source: Elections Canada) Middlesex-London 042825_Lianne Rood middlesex London candidate federal election The riding of Middlesex-London has re-elected Conservative Lianne Rood to another term. Party Candidate Votes Percentage PC Lianne Rood* 3,387 54.7 LIB Kent Keenan 2,300 37.1 GRN Jim Johnston 111 1.8 PPC Cynthia Workman 63 1.0 NDP Taylor McIntosh 297 4.8 UPC Shawn Cartlidge 34 0.5 *Indicates incumbent 032425_london election ridings districts population area middlesex centre The riding of London Centre (Source: Elections Canada) London Centre Liberal incumbent Peter Fragiskatos has been re-elected in the riding of London Centre. 042825_London centre federal election winner Peter Fragiskatos Party Candidate Votes Percentage LIB Peter Fragiskatos* 2,851 54.5 PC Stephen Gallant 1,699 32.5 GRN Mary Ann Hodge 106 2.0 NDP Dirka Prout 499 9.5 PPC David Annis 65 1.2 CFP Bruce Lamb 8 0.2 032425_london election ridings districts population area middlesex centre The riding of London-Fanshawe (Source: Elections Canada) London-Fanshawe This riding covers a large section of London's east end. Across the 107 square kilometres, 126,286 residents live in London-Fanshawe with 89,642 electors. The riding had a span of Liberal leadership from its inception in 1997 until 2006 when the NDP took over. It's been NDP orange ever since. Party Candidate Votes Percentage NDP Lindsay Mathyssen* 1,086 29.1 PC Kurt Holman 1,584 42.4 LIB Najam Naqvi 1,010 27 PPC Daniel Buta 56 1.5 040325_London-Fanshawe federal election candidates London-Fanshawe candidates (L-R): Lindsay Mathyssen (NDP), Kurt Holman (CON), Najam Naqvi (LIB), Daniel Buta (PPC) Lindsay Mathyssen – NDP Mathyssen currently serves as the deputy house leader and the critic for National Defence. She previously served as critic for Women and Gender Equality and is currently the deputy critic in this portfolio. She earned an Honours Bachelors Degree from Queen's University and later a Professional Certificate in Not-for-Profit Management from the University of Western Ontario. She was first elected in 2019 when she succeeded her mother Irene Mathyssen, who held office for the NDP from 2006 until 2019. Kurt Holman – Conservative Holman has over 20 years of experience in IT management and support and is a long-time resident of London and member of the London-Fanshawe Conservative Association. Holman completed his Computer Engineering Technology diploma at Lambton College. He also earned his Executive MBA through McMaster's DeGroote School of Business. Najam Naqvi – Liberal Born in Pakistan, Naqvi came to London in 2000 as a trained lawyer. After passing the bar in Ontario in 2022, Naqvi opened his own law firm in London. He joined the Liberal Party in 2001 and has volunteered for candidates at multiple levels of government. Daniel Buta – PPC Born in 1978 in Romania, Buta immigrated to Canada in 1991. He later attended Conestoga College, where he studied CNC programming and manufacturing engineering. He has worked in various fields, including six years as a professor at Conestoga College. London West election riding London West The riding of London West may be the smallest in the city, at just 62 square kilometres, a population of 114,374 with 83,361 electors, but it's also the oldest riding. It's been represented in the House of Commons since 1968. The riding has largely been represented by Liberals since its inception, with only four terms won by Conservatives. Party Candidate Votes Percentage LIB Arielle Kayabaga* 1,398 48.7 PC Adam Benni 1,189 41.4 NDP Shinade Allder 219 7.6 GRN Jeff Vanderzwet 30 1 CFP Russell Benner 16 0.6 UPC Christine Oliver 17 0.6 040425_London west election riding candidates London West candidates (L-R): Arielle Kayabaga (LIB), Adam Benni (PC), Shinade Allder (NDP), Jeff Vanderzwet (GRN | No photo available) Arielle Kayabaga – Liberal Kayabaga was the first Black woman ever elected as Member of Parliament (2021) in London and to London City Council (2018). She earned her Bachelor of Arts in Political Science from Carleton University. Kayabaga was selected as a 2023 Young Global Leader by the World Economic Forum and honoured as Politician of the Year by One Young World. She also is the current co-chair of the Global Cooperation Caucus, and the chair of Liberal Black Caucus. Adam Benni – Conservative Benni has over 30 years of work experience in mortgage product development and commercial and retail banking. He has also served on the board of the London West Conservative Riding Association. Benni also teaches courses at the Lawrence Kinlin School of Business at Fanshawe College. He has earned a degree in Political Science from the University of Western Ontario and an MBA from the Manchester Alliance Business School in the UK. Shinade Allder – NDP Allder has a seasoned history as a part of the labour movement, and was the first woman and first person of colour elected as Unifor's Ontario Regional Council Chair in 2022. She currently serves as president of Unifor Local 6005, representing those from Bell Canada Clerical, and the London Cross Cultural Learner Centre. She has earned several awards for her activism including the Platinum Jubilee Award, the International Woman Achievers Award, and the Leading Women Leading Girls Award from London West MPP Peggy Sattler. Jeff Vanderzwet – Green A description of Jeff Vanderzwet is unavailable at this time. 032425_london election ridings districts population area middlesex centre The riding of Elgin-St. Thomas-London South (Source: Elections Canada) Elgin-St. Thomas-London South The new riding of Elgin-St. Thomas-London South includes parts of London, takes in St. Thomas, and spans the length of Elgin County. From high-rises and new housing, to farmland and roundabouts - the new ridings serve up a mix of geography and demographics with a population of 112,448. Party Candidate Votes Percentage PC Andrew Lawton 3,868 49.4 LIB David Goodwin 3,380 43.2 PPC Stephen Campbell 184 2.3 NDP Paul Pighin 400 5.1 041425_Elgin st thomas london south election candidates federal Candidates for Elgin-St. Thomas-London South (L-R): Andrew Lawton (CON), David Goodwin (LIB), Stephen Campbell (PPC), Paul Pighin (NDP) Andrew Lawton - Conservative Lawton has experience as a journalist and broadcaster. He was previously the managing editor of True North. Before that, he hosted a daily talk radio show on 980 CFPL in London. Lawton says he is passionate about mental health, and volunteers on the board of Suicide Prevention Middlesex-London. He has a degree in political science and history from the University of Western Ontario and worked as a journalism instructor at Wilfrid Laurier University. David Goodwin - Liberal Goodwin was born and raised in Elgin County. He has a history in the finance sector. He graduated from Wilfred Laurier University and also holds a diploma in Data Analytics from the University of Toronto's Rotman School of Management. Goodwin was the chair/president of the Elgin-St. Thomas-London South Federal Liberal Association and currently serves as vice president/treasurer. Stephen Campbell - PPC Campbell was raised in the farming community of North Ekfrid. He graduated from high school in Glencoe before earning a Business Diploma and an Information Systems Diploma from Fanshawe College. Paul Pighin - NDP Pighin grew up in London, and as a young athlete competed on the Canadian National Gymnsatics Team, retiring after World Championships in 1991. Diagnosed with HIV in 1994, Pighin underwent treatment in a period of stigma surrounding the virus, and now serves as an advocate for people living with HIV/AIDS, and for the 2SLGHTQI+ community, as well as people with disabilities. His political background lies in his service as constituency assistant to Irene Mathyssen and Lindsay Mathyssen.
Yahoo
23-04-2025
- Politics
- Yahoo
Lawyers got most of £25m to settle legacy cases
The Police Service of Northern Ireland (PSNI) paid out £25m to settle civil cases related to the Troubles in recent years and most of it went to lawyers, the chief constable has told MPs. Jon Boutcher said lawyers received almost £18m - more than double the amount obtained by victims who brought the claims. He was giving evidence to the Northern Ireland Affairs Committee. Mr Boutcher described legacy as "a green field site for lawyers" due to "an attritional approach by all the security agencies around information disclosure". Mr Boutcher said the PSNI was not properly funded for legacy issues and the costs would pay for the recruitment of hundreds of extra officers. The PSNI's costs cover not just court cases, but also operating its Legacy Investigations Branch (LIB). "We are spending just over £20m a year. That would be about 400 police officers," he said. "But we've been left with this millstone, this anchor, that holds the PSNI back. "It is a considerable burden on us." The PSNI is currently dealing with 1,100 civil actions - in 2014 the figure was 150. The head of its LIB, detective chief superintendent Claire McGuigan, said: "We don't have anywhere near the resources to deal with those, nor the money to settle them. "We're in a position that is very, very difficult and it doesn't build trust in the community because it looks like we are stalling." She said the PSNI continues to have "obligations" despite the Legacy Act passing Troubles' cases to a new body, the Independent Commission for Reconciliation and Information Recovery (ICRIR). The former Police Ombudsman, Nuala O'Loan, also gave evidence to the committee. She told the committee it was unreasonable to expect the PSNI to use "today's budget to fund yesterday's cases". "The government really need to be ready to set aside a specific budget for these matters," she said.
